FDA Approves FLUORESCEIN — BPI Labs LLC

# FDA Approves BPI Labs' Generic Fluorescein Sodium for Intravenous Use The FDA has approved BPI Labs LLC's abbreviated new drug application for generic fluorescein sodium injection, potentially opening the door to increased competition in the diagnostic imaging market and offering cost savings for healthcare providers administering angiography and ophthalmology procedures. The approval of the intravenous formulation expands treatment options in a market segment previously dominated by branded alternatives.